The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in ...
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots?
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...
MedPage Today on MSN9d
Add-On Metformin Promising in ER-Positive Endometrial CancerAdding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...
A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...
Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback